{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:25:15Z","timestamp":1794468315802,"version":"4.9.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019009","name":"Francophone Foundation for Diabetes Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.diabet.2025.101683","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:03:36Z","timestamp":1751713416000},"page":"101683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Post-translational modifications of apolipoproteins as promising biomarkers for diabetes-related cardiovascular diseases: A comprehensive review"],"prefix":"10.1016","volume":"51","author":[{"given":"Chlo\u00e9","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00eanio","family":"Rodrigues Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Le May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-5817","authenticated-orcid":false,"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101683_bib0001","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk Factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0002","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.2337\/DC12-2501","article-title":"Diabetes prevention and treatment strategies: are we doing enough?","volume":"36","author":"Backholer","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrendo.2011.183","article-title":"The worldwide epidemiology of type 2 diabetes mellitus\u2013present and future perspectives","volume":"8","author":"Chen","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2025.101683_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.diabet.2025.101683_bib0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: united Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2025.101683_bib0006","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101683_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101066","article-title":"Identification and characterization of post-translational modifications: clinical implications","author":"Hermann","year":"2022","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0008","article-title":"Irreversible post-translational modifications - Emerging cardiovascular risk factors","author":"Wu","year":"2021","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/proteomes5040027","article-title":"Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes","volume":"5","author":"Nedelkov","year":"2017","journal-title":"Proteomes"},{"key":"10.1016\/j.diabet.2025.101683_bib0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","article-title":"Apolipoproteins in vascular biology and atherosclerotic disease","volume":"19","author":"Mehta","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0011","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14789450.2017.1374859","article-title":"Advances in quantifying apolipoproteins using LC-MS\/MS technology: implications for the clinic","volume":"14","author":"van den Broek","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.diabet.2025.101683_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1194\/jlr.P083576","article-title":"Kinetics of plasma apolipoprotein E isoforms by LC-MS\/MS: a pilot study","volume":"59","author":"Blanchard","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0014","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jacl.2016.03.001","article-title":"Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes","volume":"10","author":"Azizkhanian","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.diabet.2025.101683_bib0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1194\/jlr.P064816","article-title":"Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes","volume":"57","author":"Koska","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0016","first-page":"18","article-title":"The Application of multiple reaction monitoring to assess apo a-i methionine oxidations in diabetes and cardiovascular disease","volume":"4\u20135","author":"Yassine","year":"2014","journal-title":"Transl Proteom"},{"key":"10.1016\/j.diabet.2025.101683_bib0017","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2337\/dc20-2186","article-title":"Carbamylated HDL and mortality outcomes in type 2 diabetes","volume":"44","author":"Lui","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0018","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/dc20-2089","article-title":"Autoantibodies against methylglyoxal-modified apolipoprotein b100 and apob100 peptide are associated with less coronary artery atherosclerosis and retinopathy in long-term type 1 diabetes","volume":"44","author":"Sveen","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0019","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/dc12-1411","article-title":"Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients","volume":"36","author":"Pu","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1258\/acb.2011.011111","article-title":"Apolipoproteins: metabolic role and clinical biochemistry applications","volume":"48","author":"Dominiczak","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.diabet.2025.101683_bib0110","first-page":"491","article-title":"Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease","volume":"3","author":"Olofsson","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.diabet.2025.101683_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(01)00751-1","article-title":"HDL metabolism and atherosclerosis","volume":"164","author":"Tailleux","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101683_bib0112","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1194\/jlr.R052753","article-title":"Apolipoprotein A-IV: a protein intimately involved in metabolism","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0113","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2796.2005.01556.x","article-title":"Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis","volume":"258","author":"Olofsson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0066","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12933-022-01703-5","article-title":"Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review","volume":"21","author":"Rouland","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2025.101683_bib0114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.diabet.2025.101683_bib0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.diabet.2025.101683_bib0116","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.diabet.2025.101683_bib0117","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101683_bib0021","series-title":"Endotext","article-title":"Introduction to Lipids and Lipoproteins","author":"Feingold","year":"2000"},{"key":"10.1016\/j.diabet.2025.101683_bib0022","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1194\/jlr.M085332","article-title":"A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL","volume":"59","author":"Cooke","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0023","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11883-022-00995-y","article-title":"Transintestinal cholesterol excretion in health and disease","volume":"24","author":"Gar\u00e7on","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.diabet.2025.101683_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lfs.2012.10.026","article-title":"Diabetes induces gender gap on LCAT levels and activity","volume":"92","author":"Nakhjavani","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.diabet.2025.101683_bib0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101683_bib0026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/diacare.17.1.6","article-title":"Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity","volume":"17","author":"Ruotolo","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0027","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1161\/01.ATV.0000146267.71816.30","article-title":"Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus","volume":"24","author":"Annuzzi","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2025.101683_bib0028","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/met.2014.0050","article-title":"Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance","volume":"12","author":"Shalaurova","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.diabet.2025.101683_bib0029","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/01.CIR.97.23.2307","article-title":"Apoptosis and related proteins in different stages of human atherosclerotic plaques","volume":"97","author":"Kockx","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101683_bib0030","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1172\/JCI117917","article-title":"Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques","volume":"95","author":"Bennett","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2025.101683_bib0031","first-page":"149","article-title":"Importance of glycation in the acceleration of low density lipoprotein (LDL) uptake into macrophages in patients with diabetes mellitus","volume":"18","author":"Makita","year":"1999","journal-title":"Int Angiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12014-018-9208-y","article-title":"Investigation of post-translational modifications in type 2 diabetes","volume":"15","author":"Chatterjee","year":"2018","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.diabet.2025.101683_bib0033","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/prca.201400052","article-title":"The role of post-translational modifications in acute and chronic cardiovascular disease","volume":"8","author":"Smith","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.diabet.2025.101683_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101053","article-title":"Biochemical genesis of enzymatic and non-enzymatic post-translational modifications","volume":"86","author":"Jennings","year":"2022","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijbiomac.2021.12.041","article-title":"A review on prevention of glycation of proteins: potential therapeutic substances to mitigate the severity of diabetes complications","volume":"195","author":"Sarmah","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.diabet.2025.101683_bib0036","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","article-title":"Glycosylation in health and disease","volume":"15","author":"Reily","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabet.2025.101683_bib0037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fcvm.2018.00070","article-title":"The regulation of insulin-stimulated cardiac glucose transport via protein acetylation","volume":"5","author":"Renguet","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019890","article-title":"Spectrum of apolipoprotein AI and apolipoprotein AII proteoforms and their associations with indices of cardiometabolic health: the CARDIA Study","volume":"10","author":"Wilkins","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2025.101683_bib0039","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-020-02623-2","article-title":"Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion","volume":"18","author":"Chen","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0040","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nm1637","article-title":"Protein carbamylation links inflammation, smoking, uremia and atherogenesis","volume":"13","author":"Wang","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0041","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13250","article-title":"Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion","volume":"7","author":"Sacco","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabet.2025.101683_bib0042","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/pmic.201500043","article-title":"The path of no return\u2014Truncated protein N-termini and current ignorance of their genesis","volume":"15","author":"Fortelny","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.diabet.2025.101683_bib0043","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/cvr\/cvaa252","article-title":"Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis","volume":"117","author":"Pirillo","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0044","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1073\/pnas.072072399","article-title":"Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes","volume":"99","author":"Vosseller","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diabet.2025.101683_bib0045","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/nature06668","article-title":"Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance","volume":"451","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2025.101683_bib0046","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.yexcr.2008.04.014","article-title":"O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic beta cells","volume":"314","author":"Kang","year":"2008","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0047","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.chemrev.6b00750","article-title":"Protein lipidation: occurrence, mechanisms, biological functions, and enabling technologies","volume":"118","author":"Jiang","year":"2018","journal-title":"Chem Rev"},{"key":"10.1016\/j.diabet.2025.101683_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.717503","article-title":"Lysine fatty acylation: regulatory enzymes, research tools, and biological function","volume":"9","author":"Komaniecki","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.diabet.2025.101683_bib0049","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cmet.2022.12.012","article-title":"Palmitoylation couples insulin hypersecretion with \u03b2 cell failure in diabetes","volume":"35","author":"Dong","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2025.101683_bib0050","doi-asserted-by":"crossref","first-page":"25869","DOI":"10.1074\/jbc.M112.375204","article-title":"Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC)","volume":"287","author":"Kadiyala","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2025.101683_bib0051","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12020-012-9795-8","article-title":"Methylglyoxal, obesity, and diabetes","volume":"43","author":"Matafome","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.diabet.2025.101683_bib0052","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.imbio.2018.11.010","article-title":"Reactive oxygen species (ROS) in macrophage activation and function in diabetes","volume":"224","author":"Rendra","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.diabet.2025.101683_bib0053","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101683_bib0054","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfv048","article-title":"Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease","volume":"30","author":"Gajjala","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2025.101683_bib0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.diabet.2017.05.006","article-title":"Carbamylation is a competitor of glycation for protein modification in vivo","volume":"44","author":"Nicolas","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101683_bib0056","doi-asserted-by":"crossref","first-page":"175ra29","DOI":"10.1126\/scitranslmed.3005218","article-title":"Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure","volume":"5","author":"Berg","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0057","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/cclm-2012-0878","article-title":"Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra-performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen","volume":"52","author":"Scheijen","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0058","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ab.2012.02.025","article-title":"Rapid and sensitive determination of the intermediates of advanced glycation end products in the human nail by ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry","volume":"424","author":"Min","year":"2012","journal-title":"Anal Biochem"},{"key":"10.1016\/j.diabet.2025.101683_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1037186","article-title":"Advanced glycation end products in diabetic retinopathy and phytochemical therapy","volume":"9","author":"Kang","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.diabet.2025.101683_bib0060","series-title":"Glycoscience: biology and medicine","first-page":"1339","article-title":"Glycation of Proteins","author":"Takahashi","year":"2015"},{"key":"10.1016\/j.diabet.2025.101683_bib0061","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nm.3459","article-title":"An abundant dysfunctional apolipoprotein A1 in human atheroma","volume":"20","author":"Huang","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2004.08.003","article-title":"Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages","volume":"177","author":"Lam","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101683_bib0063","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1742-4658.2007.05699.x","article-title":"Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages","volume":"274","author":"Brown","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.diabet.2025.101683_bib0064","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2337\/db11-0085","article-title":"Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes","volume":"60","author":"Rabbani","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101683_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yjmcc.2018.08.001","article-title":"Lysine glycation of apolipoprotein A-I impairs its anti-inflammatory function in type 2 diabetes mellitus","volume":"122","author":"Liu","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0067","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.2337\/dc13-1467","article-title":"Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes","volume":"37","author":"Bouillet","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101832","article-title":"The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta","volume":"298","author":"Battle","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2025.101683_bib0069","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1089\/ars.2010.3640","article-title":"Protein carbamylation renders high-density lipoprotein dysfunctional","volume":"14","author":"Holzer","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.diabet.2025.101683_bib0070","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1016\/S0021-9258(18)53318-4","article-title":"O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins","volume":"268","author":"Remaley","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2025.101683_bib0071","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","article-title":"Mass spectrometry-based proteomics","volume":"422","author":"Aebersold","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2025.101683_bib0072","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","article-title":"Plasma proteome profiling to assess human health and disease","volume":"2","author":"Geyer","year":"2016","journal-title":"Cell Syst"},{"key":"10.1016\/j.diabet.2025.101683_bib0073","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1373\/clinchem.2009.126706","article-title":"The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum","volume":"56","author":"Anderson","year":"2010","journal-title":"Clin Chemistry"},{"key":"10.1016\/j.diabet.2025.101683_bib0074","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/gm457","article-title":"The emergence of top-down proteomics in clinical research","volume":"5","author":"Savaryn","year":"2013","journal-title":"Genome Med"},{"key":"10.1016\/j.diabet.2025.101683_bib0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nprot.2016.057","article-title":"Six alternative proteases for mass spectrometry-based proteomics beyond trypsin","volume":"11","author":"Giansanti","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.diabet.2025.101683_bib0076","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14789450.2017.1374859","article-title":"Advances in quantifying apolipoproteins using LC-MS\/MS technology: implications for the clinic","volume":"14","author":"van den Broek","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.diabet.2025.101683_bib0078","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diabet.2017.04.003","article-title":"Fenofibrate decreases plasma ceramide in type 2 diabetes patients: a novel marker of CVD?","volume":"44","author":"Croyal","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101683_bib0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12933-022-01452-5","article-title":"Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes","volume":"21","author":"Croyal","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2025.101683_bib0080","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/prca.201300034","article-title":"Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC-MS\/MS","volume":"7","author":"Ceglarek","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.diabet.2025.101683_bib0081","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700279","article-title":"Targeted on-line SPE-LC-MS\/MS assay for the quantitation of 12 apolipoproteins from human blood","volume":"18","author":"Dittrich","year":"2018","journal-title":"Proteomics"},{"key":"10.1016\/j.diabet.2025.101683_bib0093","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2005.11.006","article-title":"Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease","volume":"113","author":"Johnston","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0094","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2022.01.005","article-title":"Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: a potential contribution to reduction in cardiovascular risk","volume":"346","author":"Iqbal","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101683_bib0095","doi-asserted-by":"crossref","DOI":"10.2337\/dc24-1462","article-title":"Relationship of plasma apolipoprotein C-I truncation with risk of diabetes in the multi-ethnic study of atherosclerosis and the actos now for the prevention of diabetes study","author":"Koska","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101683_bib0096","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/ATVBAHA.123.319035","article-title":"Apo CIII proteoforms, plasma lipids, and cardiovascular risk in MESA","volume":"43","author":"Sinari","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2025.101683_bib0097","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacl.2016.12.009","article-title":"Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions","volume":"11","author":"Mendoza","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.diabet.2025.101683_bib0077","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1194\/jlr.D120000835","article-title":"A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins","volume":"61","author":"Blanchard","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0082","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacbts.2019.03.002","article-title":"Reduced lipoprotein(a) associated with the apolipoprotein E2 genotype confers cardiovascular protection in familial hypercholesterolemia","volume":"4","author":"Blanchard","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabet.2025.101683_bib0083","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1194\/jlr.P083576","article-title":"Kinetics of plasma apolipoprotein E isoforms by LC-MS\/MS: a pilot study","volume":"59","author":"Blanchard","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0084","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabet.2025.101683_bib0085","first-page":"hvaf035","article-title":"Methylglyoxal-Induced glycation of plasma albumin: from biomarker discovery to clinical use for prediction of new-onset diabetes in individuals with prediabetes","author":"Rodrigues Oliveira","year":"2025","journal-title":"Clin Chem"},{"key":"10.1016\/j.diabet.2025.101683_bib0086","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1021\/acs.jproteome.8b00100","article-title":"A targeted, differential top-down proteomic methodology for comparison of ApoA-I proteoforms in individuals with high and low HDL efflux capacity","volume":"17","author":"Seckler","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100263","article-title":"Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis","volume":"63","author":"Koska","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cca.2015.01.011","article-title":"A fast semi-quantitative LC-MS method for measurement of intact apolipoprotein A-I reveals novel proteoforms in serum","volume":"442","author":"G\u00e5fvels","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.diabet.2025.101683_bib0119","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/pr401074t","article-title":"Top-down proteomics of a drop of blood for diabetes monitoring","volume":"13","author":"Mao","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0120","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.bbadis.2018.05.014","article-title":"Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism","volume":"1864","author":"Domingo-Esp\u00edn","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.diabet.2025.101683_bib0121","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1038\/nutd.2014.31","article-title":"Arginine-directed glycation and decreased HDL plasma concentration and functionality","volume":"4","author":"Godfrey","year":"2014","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.diabet.2025.101683_bib0122","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/ac3034757","article-title":"Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry","volume":"85","author":"Jian","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.diabet.2025.101683_bib0123","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/prca.201400187","article-title":"MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis","volume":"9","author":"Yen-Nicola\u00ff","year":"2015","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.diabet.2025.101683_bib0124","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/acs.jproteome.7b00604","article-title":"Targeted measurements of O- and N-glycopeptides show that proteins in high density lipoprotein particles are enriched with specific glycosylation compared to plasma","volume":"17","author":"Kailemia","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0088","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2215\/CJN.11710919","article-title":"Carbamylated lipoproteins and progression of diabetic kidney disease","volume":"15","author":"Tan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2025.101683_bib0089","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.trsl.2014.03.008","article-title":"Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction","volume":"164","author":"Cubedo","year":"2014","journal-title":"Transl Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0090","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1021\/acs.jproteome.5b00730","article-title":"Combined high-density lipoprotein proteomic and glycomic profiles in patients at risk for coronary artery disease","volume":"14","author":"Krishnan","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.diabet.2025.101683_bib0091","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.104.529297","article-title":"Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population","volume":"112","author":"Meisinger","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101683_bib0092","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2004.01.029","article-title":"Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease","volume":"174","author":"Shimada","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101683_bib0098","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0026-0495(00)80082-7","article-title":"Oxidative stress and glycemic regulation","volume":"49","author":"Ceriello","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101683_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105892","volume":"90","author":"Reutens","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.diabet.2025.101683_bib0100","doi-asserted-by":"crossref","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.diabet.2025.101683_bib0101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabet.2025.101683_bib0102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabet.2025.101683_bib0103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.2011.06320.x","article-title":"Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications","volume":"1243","author":"Ramasamy","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.diabet.2025.101683_bib0104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2014.04.034","article-title":"Protein carbamylation in kidney disease: pathogenesis and clinical implications","volume":"64","author":"Kalim","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2025.101683_bib0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14779072.2020.1768848","article-title":"Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia","volume":"18","author":"Nurmohamed","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.diabet.2025.101683_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.751637","article-title":"An overview of glycosylation and its impact on cardiovascular health and disease","volume":"8","author":"Loaeza-Reyes","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.diabet.2025.101683_bib0107","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1002\/mco2.261","article-title":"Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications","volume":"4","author":"Zhong","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.diabet.2025.101683_bib0108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fendo.2018.00642","article-title":"Chronic O-GlcNAcylation and diabetic cardiomyopathy: the bitterness of glucose","volume":"9","author":"Ducheix","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101683_bib0109","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.3390\/ijms25105365","article-title":"Apolipoprotein-CIII O-Glycosylation is associated with micro- and macrovascular complications of type 2 diabetes","volume":"25","author":"Naber","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:45:52Z","timestamp":1753310752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1262363625000771"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101683","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-translational modifications of apolipoproteins as promising biomarkers for diabetes-related cardiovascular diseases: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101683"}}